Johnson & Johnson agreed to acquire Intra-Cellular Therapies for $132 a share in cash for a total equity value of about $14.6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback